65th ASH Annual Meeting & Exposition

• Supplied study files

  The detailed list below describes the stored package inventory; it does not grant access to the official ASH webcast platform or establish continuing-education eligibility.

 Topics:

• Education Program Acquired Hemophilia A Diagnosis and Management Andreas Tiede-24122.pdf
• Education Program Acquired Hemophilia A Diagnosis and Management Rebecca Kruse-Jarres-24122.pdf
• Education Program Acquired Hemophilia A Diagnosis and Management Sean Platton-24122.pdf
• Education Program Acquired Hemophilia A Diagnosis and Management.ts
• Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Ashish Kumar-24117.pdf
• Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Clifford Takemoto-24117.pdf
• Education Program Alphabet Soup – Challenging Consults on the Pediatric Units Nicole Kucine-24117.pdf
• Education Program Alphabet Soup – Challenging Consults on the Pediatric Units.ts
• Education Program Are We Personalizing MDS Therapy in 2023 David Sallman-24106.pdf
• Education Program Are We Personalizing MDS Therapy in 2023 Marie Sebert-24106.pdf
• Education Program Are We Personalizing MDS Therapy in 2023 Rena Xian-24106.pdf
• Education Program Are We Personalizing MDS Therapy in 2023.ts
• Education Program CAR T Cells in ALL Bridge or Definitive Therapy Alice Bertaina-24107.pdf
• Education Program CAR T Cells in ALL Bridge or Definitive Therapy Nirali Shah-24107.pdf
• Education Program CAR T Cells in ALL Bridge or Definitive Therapy Stephen Gottschalk-24107.pdf
• Education Program CAR T Cells in ALL Bridge or Definitive Therapy.ts
• Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Eduard Van Beers-24125.pdf
• Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Kevin Kuo-24125.pdf
• Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Rachael Grace-24125.pdf
• Education Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias.ts
• Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kasiani Myers-24118.pdf
• Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kristen Schratz-24118.pdf
• Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Suneet Agarwal-24118.pdf
• Education Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right.ts
• Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Idoroenyi Amanam-24100.pdf
• Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Kirk Schultz-24100.pdf
• Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Muna Qayed-24100.pdf
• Education Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure.ts
• Education Program Have We Optimized Therapy Yet for Patients with AML Justin Watts-24104.pdf
• Education Program Have We Optimized Therapy Yet for Patients with AML Tara Lin-24104.pdf
• Education Program Have We Optimized Therapy Yet for Patients with AML.ts
• Education Program Hematologic Toxicity of Immunotherapies Frederick Locke-24113.pdf
• Education Program Hematologic Toxicity of Immunotherapies Martin Hutchings-24113.pdf
• Education Program Hematologic Toxicity of Immunotherapies Michael Kroll-24113.pdf
• Education Program Hematologic Toxicity of Immunotherapies.ts
• Education Program Hematologists and the Care of Pregnant Women Adam Lewkowitz-24121.pdf
• Education Program Hematologists and the Care of Pregnant Women Andra James-24121.pdf
• Education Program Hematologists and the Care of Pregnant Women Fionnuala Ni Ainle-24121.pdf
• Education Program Hematologists and the Care of Pregnant Women.ts
• Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Adi Zoref-Lorenz-24124.pdf
• Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Martin Tallman-24124.pdf
• Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies Steven Fein-24124.pdf
• Education Program Hematologists as Lifesavers Inpatient Hematology Emergencies.ts
• Education Program Hemostasis in Patients With Severe Liver Disease Lara Roberts-24123.pdf
• Education Program Hemostasis in Patients With Severe Liver Disease Ton Lisman-24123.pdf
• Education Program Hemostasis in Patients With Severe Liver Disease Walter Ageno-24123.pdf
• Education Program Hemostasis in Patients With Severe Liver Disease.ts
• Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Darja Karpova-24119.pdf
• Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Mindy Goldman-24119.pdf
• Education Program Hot Topics in Blood Donation Donor Risks and Social Justice Richard Kaufman-24119.pdf
• Education Program Hot Topics in Blood Donation Donor Risks and Social Justice.ts
• Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Dipti Patel-Donnelly-24110.pdf
• Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Jesus Berdeja-24110.pdf
• Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community Ruemu Birhiray-24110.pdf
• Education Program How Can We Manage High-Risk Hematologic Malignancies in the Community.ts
• Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Nizar Bahlis-24102.pdf
• Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Sham Mailankody-24102.pdf
• Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Surbhi Sidana-24102.pdf
• Education Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies.ts
• Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Anna Maria Sureda Balari-24097.pdf
• Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Loretta Nastoupil-24097.pdf
• Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Manali Kamdar-24097.pdf
• Education Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023.ts
• Education Program How Do We Enhance Results in Rare Hematologic Malignancies Anita DSouza-24112.pdf
• Education Program How Do We Enhance Results in Rare Hematologic Malignancies Deepti Radia-24112.pdf
• Education Program How Do We Enhance Results in Rare Hematologic Malignancies Oussama Abla-24112.pdf
• Education Program How Do We Enhance Results in Rare Hematologic Malignancies.ts
• Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Chaitra Ujjani-24111.pdf
• Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Joanna Rhodes-24111.pdf
• Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Toby Eyre-24111.pdf
• Education Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023.ts
• Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Adam Cohen-24103.pdf
• Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Francesca Gay-24103.pdf
• Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Monique Hartley-Brown-24103.pdf
• Education Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023.ts
• Education Program How Do We Tackle Remaining Clinical Challenges in CML Massimo Breccia-24109.pdf
• Education Program How Do We Tackle Remaining Clinical Challenges in CML Naranie Shanmuganathan-24109.pdf
• Education Program How Do We Tackle Remaining Clinical Challenges in CML Simona Soverini-24109.pdf
• Education Program How Do We Tackle Remaining Clinical Challenges in CML.ts
• Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Andrew Evens-24098.pdf
• Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Natalie Grover-24098.pdf
• Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Sairah Ahmed-24098.pdf
• Education Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023.ts
• Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Adetola Kassim-24127.pdf
• Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle John Tisdale-24127.pdf
• Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Kenneth Ataga-24127.pdf
• Education Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle.ts
• Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Emma Groarke-24126.pdf
• Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Marena Niewisch-24126.pdf
• Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Timothy Olson-24126.pdf
• Education Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult.ts
• Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Emily Curran-24108.pdf
• Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL John Molina-24108.pdf
• Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Tamara Miller-24108.pdf
• Education Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL.ts
• Education Program Ongoing Challenges in the Management of VTE Cecilia Becattini-24115.pdf
• Education Program Ongoing Challenges in the Management of VTE Keith McCrae-24115.pdf
• Education Program Ongoing Challenges in the Management of VTE Kenneth Bauer-24115.pdf
• Education Program Ongoing Challenges in the Management of VTE.ts
• Education Program The Iron Revolution Jacquelyn Powers-24116.pdf
• Education Program The Iron Revolution Michael Auerbach-24116.pdf
• Education Program The Iron Revolution Thomas Deloughery-24116.pdf
• Education Program The Iron Revolution.ts
• Education Program Transfusion Support in Sickle Cell Disease Anoosha Habibi-24120.pdf
• Education Program Transfusion Support in Sickle Cell Disease France Pirenne-24120.pdf
• Education Program Transfusion Support in Sickle Cell Disease Shannon Kelly-24120.pdf
  Education Program Transfusion Support in Sickle Cell Disease.ts
  Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Douglas Tremblay-24099.pdf
  Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Harinder Gill-24099.pdf
  Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Jeanne Palmer-24099.pdf
  Education Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management.ts
  Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Alison Walker-24105.pdf
  Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Jacqueline Cloos-24105.pdf
  Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Marion Subklewe-24105.pdf
  Education Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML.ts
  Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Asmita Mishra-24101.pdf
  Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Reena Jayani-24101.pdf
  Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Roni Shouval-24101.pdf
  Education Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together.ts
  Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Jennifer McIntosh-24114.pdf
  Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Shruti Chaturvedi-24114.pdf
  Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies TBD Retter-24114.pdf
  Education Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies.ts
  General Sessions ASH-EHA Joint Symposium Alexander Medvinsky-24135.pdf
  General Sessions ASH-EHA Joint Symposium Linheng Li-24135.pdf
  General Sessions ASH-EHA Joint Symposium.ts
  General Sessions E. Donnall Thomas Lecture and Prize Katayoun Rezvani-24174.pdf
  General Sessions E. Donnall Thomas Lecture and Prize.ts
  General Sessions Ernest Beutler Lecture and Prize Johnny Mahlangu-24175.pdf
  General Sessions Ernest Beutler Lecture and Prize Takehisa Kitazawa-24175.pdf
  General Sessions Ernest Beutler Lecture and Prize.ts
  General Sessions Ham-Wasserman Lecture Andreas Greinacher-24133.pdf
  General Sessions Ham-Wasserman Lecture.ts
  General Sessions Late Breaking Abstracts Adetola Kassim-25508.pdf
  General Sessions Late Breaking Abstracts Hamish Scott-25508.pdf
  General Sessions Late Breaking Abstracts Ibrahim Aldoss-25508.pdf
  General Sessions Late Breaking Abstracts Keith McCrae-25508.pdf
  General Sessions Late Breaking Abstracts Michael Wang-25508.pdf
  General Sessions Late Breaking Abstracts Pieter Sonneveld-25508.pdf
  General Sessions Late Breaking Abstracts.ts
  General Sessions Plenary Scientific Session Banu Aygun-25390.pdf
  General Sessions Plenary Scientific Session Betty Pace-25390.pdf
  General Sessions Plenary Scientific Session Brian Krum-25390.pdf
  General Sessions Plenary Scientific Session Daniel Wolff-25390.pdf
  General Sessions Plenary Scientific Session Francesca Gay-25390.pdf
  General Sessions Plenary Scientific Session Isaac Odame-25390.pdf
  General Sessions Plenary Scientific Session Pamela Ting-25390.pdf
  General Sessions Plenary Scientific Session Peter Voorhees-25390.pdf
  General Sessions Plenary Scientific Session Salima Benbarche-25390.pdf
  General Sessions Plenary Scientific Session Stefanie Sarantopoulos-25390.pdf
  General Sessions Plenary Scientific Session Stephanie Halene-25390.pdf
  General Sessions Plenary Scientific Session Trista North-25390.pdf
  General Sessions Plenary Scientific Session.ts
  General Sessions Presidential Symposium Claudia Kemper-24134.pdf
  General Sessions Presidential Symposium Eleni Gavriilaki-24134.pdf
  General Sessions Presidential Symposium Lubka Roumenina-24134.pdf
  General Sessions Presidential Symposium.ts
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Hsiang-Ying Lee-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Lei Yu-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Marlies Rossmann-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Meng Zhang-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Vincent Schulz-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Xiurui Lv-24504.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation.ts
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rajesh Gunage-24503.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rebecca Griffiths-24503.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Xu Han-24503.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yajing Chu-24503.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yuefeng Tang-24503.pdf
  Oral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease.ts
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Caroline Philpott-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Gayle Ross-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Ilona Kleine Budde-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Rachel Josselsohn-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Tomas Ganz-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Veena Sangkhae-24505.pdf
  Oral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis.ts
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Alfonso Fernandez-24506.pdf
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Eugene Khandros-24506.pdf
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Ginette Balbin-Cuesta-24506.pdf
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Pinyaphat Khamphikham-24506.pdf
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Yu Wang-24506.pdf
  Oral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia.ts
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Auria Godard-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Boya Liu-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Britney Hernandez-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Luisanna Sanchez Ventura-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Mira Pochron-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Scott Peslak-24507.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease.ts
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Anton Ilich-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Christopher Chambliss-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Jason Sutin-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Malgorzata Kasztan-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Marissa Traets-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Suruchi Salgar-24508.pdf
  Oral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans.ts
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Alan Anderson-24511.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Angela Rankine-Mullings-24511.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Pablo Pelinski-24511.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Robyn Cohen-24511.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Sophie Lanzkron-24511.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation.ts
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Miguel Abboud-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Modupe Idowu-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Nirmish Shah-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Santosh Saraf-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Shubaya Naggayi-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Swee Lay Thein-24512.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease.ts
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Anna Sowa-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Dunia Hatabah-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Julie Kanter-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mariane De Montalembert-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mehndi Dandwani-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Modupe Idowu-24509.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors.ts
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Clare Zarka-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Jackie Queen-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Justin Yoo-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Kristine Karkoska-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Martha Kenney-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Ryan Sun-24510.pdf
  Oral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future.ts
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Adi Zoref-Lorenz-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Chen Li-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Coralie Bloch-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Misato Komori-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Ningning Zhang-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Peter Dimitrion-24514.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes.ts
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Christina Simoglou Karali-24513.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Danielle Arnold-24513.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Malte Ritter-24513.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Vahagn Makaryan-24513.pdf
  Oral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias.ts
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Benjamin Babcock-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Carlos Bravo-Perez-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Dandan Wang-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Francesco Saettini-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Mei Yu-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Melissa Mavers-24515.pdf
  Oral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity.ts
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Anish Sharda-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Huichun Zhan-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Junmei Chen-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Kelsey Sack-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Luke Dunaway-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Nilesh Pandey-24518.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis.ts
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Adam Kanack-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Caitlin Schneider-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Cristobal Rivera-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Meghna Naik-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Moua Yang-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Yvonne Kong-24517.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis.ts
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Anthony Washington-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Harvey Roweth-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Heng Mei-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Jianlin Qiao-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Lauren Murphy-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Yuxiu Chen-24516.pdf
  Oral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias.ts
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Ahmad Tarawah-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anna Frandsen-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anne Juhl-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes David Kuter-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Elizabeth King-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Hanny Al-Samkari-24521.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes.ts
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Catherine Broome-24519.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Michael Tarantino-24519.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Min Xu-24519.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Nichola Cooper-24519.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Yun Wang-24519.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia.ts
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Bertrand Godeau-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Cy Wilkins-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Etienne Crickx-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Taylor Kim-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yoann Zadro-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yuxiu Chen-24520.pdf
  Oral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations.ts
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Aleksandr Shamanaev-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Lucas Van Gorder-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Meng-Ni Fan-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Shekhar Kumar-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Thomas Girard-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Wenjing Cao-24522.pdf
  Oral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies.ts
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Davide Matino-24525.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Evelien Krumb-24525.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Guy Young-24525.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Marilyn Manco-Johnson-24525.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Yeu-Chin Chen-24525.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care.ts
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Allison Wheeler-24523.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Ferdows Atiq-24523.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Lynn Malec-24523.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Steven Pipe-24523.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan.ts
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Aditi Sharma-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Anthony Chan-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Ellen Zhang-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Eva Leinoe-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Rachel Kronenfeld-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Valentina Restrepo-24524.pdf
  Oral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders.ts
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Kenki Saito-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marie Scully-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marissa Schraner-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Maryam Subhan-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Omid Peyvandi-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Senthil Sukumar-24526.pdf
  Oral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations.ts
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Bec.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Jus.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Kri.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care She.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Sim.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care.ts
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Amelia Haj-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Gary Woods-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Julie Jaffray-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Justine Ryu-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Sacha Belinda Mapombo Choupa-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Vilmarie Rodriguez-24528.pdf
  Oral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism.ts
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Lise McQuilten-24529.pdf
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Matthew Tanner-24529.pdf
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Nanyan Zhang-24529.pdf
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Patricia Davenport-24529.pdf
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Slim Azouzi-24529.pdf
  Oral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine.ts
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alejandro Roisman-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alison Livada-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Helen Wang-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Stephanie Hurwitz-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Takao Yogo-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Tanner Martinez-24781.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness.ts
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Aditya Barve-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Karolina Vanickova-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Maegan Capitano-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Md Akram Hossain-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Virginia Camacho-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Yiran Meng-24530.pdf
  Oral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress.ts
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Lynn Quek-24532.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Nikolaos Sousos-24532.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Saravanan Ganesan-24532.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Sean Wen-24532.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries.ts
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Adriana Chiaramida-24531.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations J. Beeler-24531.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Johannes Damm-24531.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Nicole Prutsch-24531.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Yifan Zhou-24531.pdf
  Oral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations.ts
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Charles Ayemoba-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Dinisha Kamble-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Eman Khatib-Massalha-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Irene Ganan-Gomez-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Rheanna Congdon-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Shoichiro Takeishi-24533.pdf
  Oral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease.ts
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Bhavisha Patel-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carlos Bravo-Perez-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carmelo Gurnari-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Masanori Yoshida-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Pedro Prata-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Yoshitaka Zaimoku-24535.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment.ts
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Antonio Risitano-24534.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Austin Kulasekararaj-24534.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Carlos de Castro-24534.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Fengkui Zhang-24534.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Jens Panse-24534.pdf
  Oral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials.ts
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc .Kendra Jackson-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Johan Flygare-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Mona M.Hosseini-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Seth Rotz-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Valeria Visconte-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Y. Lucy Liu-24536.pdf
  Oral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc..ts
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Bac Viet Le-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Chun-Wei Chen-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Qingyu Luo-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Thomas Koehnke-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xiangguo Shi-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xin He-24538.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells.ts
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Ayana Kon-24537.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Cailin Collins-24537.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jane Xu-24537.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jie Bai-24537.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jonny Mendoza-Castrejon-24537.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy.ts
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Dorien Pastoors-24539.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Luca Nunzio Cifarelli-24539.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Madeline Niederkorn-24539.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Prajwal Boddu-24539.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Yu-Hsuan Chang-24539.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics.ts
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Amanda Tajik-24540.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Cl‚ment Larrue-24540.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Daiki Karigane-24540.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Junya Sango-24540.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Sarah Skuli-24540.pdf
  Oral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms.ts
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Darko Barisic-24541.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Gabriel Brisou-24541.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Mirca Saurty-Seerunghen-24541.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Ruifeng Sun-24541.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Sergio Roa-24541.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis.ts
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression I-Jun Lau-24542.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Marta Fernandes-24542.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Nataly Cruz-Rodriguez-24542.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Qi Jin-24542.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Vera Poort-24542.pdf
  Oral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression.ts
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Claudia Cabrera-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Eric Vick-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Karanpreet Bhatia-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Lei Zhang-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Sana Chaudhry-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Tim Kong-24545.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies.ts
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Kedwin Ventura-24543.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Li Du-24543.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Priyanka Sharma-24543.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Satoshi Kaito-24543.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Zhixiang Chen-24543.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies.ts
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Anagha Sheth-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Juan Jose Rodriguez Sevilla-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Vincent Rondeau-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Xinyue Zhou-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yi Zhang-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yuki Nishida-24544.pdf
  Oral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies.ts
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Damian Green-24546.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Keito Suto-24546.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Leandro Cerchietti-24546.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Nathan Beals-24546.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Selina Chen-Kiang-24546.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma.ts
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Britten Gordon-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Giulia Veltri-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Gregory Crimmins-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Jasmeet Sidhu-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Qin Li-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Thomas Lew-24547.pdf
  Oral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias.ts
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Aman Wadhwa-24548.pdf
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Motohiro Kato-24548.pdf
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Noam Kopmar-24548.pdf
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Sarah Elitzur-24548.pdf
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Stuart Winter-24548.pdf
  Oral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL.ts
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Curtis Lachowiez-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Enrico Attardi-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Pinkal Desai-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Rabea Mecklenbrauck-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Vikram Dhillon-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Wajma Shahbaz-24549.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related.ts
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Erika Cattaneo-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Georgina Gener-Ricos-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Himachandana Atluri-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Matthew Schwede-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Riya Sinha-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Xin Wang-24550.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI.ts
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Alex Bataller-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Constance Baer-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Marius Bill-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Niek Van Der Maas-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Richard Aplenc-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Yazan Abu-Shihab-24551.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication.ts
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Cameron Hunter-24552.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches David Grinblatt-24552.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches James Foran-24552.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Talha Badar-24552.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Zofia Gross-24552.pdf
  Oral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches.ts
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jayastu Jain-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jonathan Webster-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Marlise Luskin-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicola Goekbuget-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicolas Boissel-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Wanda Salzer-24554.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL.ts
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Karen Rabin-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Martin Schrappe-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Nicola Goekbuget-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Sabina Chiaretti-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Tanja Gruber-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Xiaoyuan Gong-24553.pdf
  Oral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL.ts
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML B. Smith-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Harry Erba-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Himachandana Atluri-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Hunault-Berger Mathilde-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Jing Lu-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Xiaohui Suo-24555.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML.ts
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Andrew Moore-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Fabio Guolo-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Franco Locatelli-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Kristoffer Hellstrand-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Li Gao-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Luca Guarnera-24557.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL.ts
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexander Perl-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexandre Kadia-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Gertjan Kaspers-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Nigel Russell-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Xiaoping Liang-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Yunxiang Zhang-24556.pdf
  Oral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML.ts
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Guillaume Richard-Carpentier-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Harinder Gill-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Leo Ruhnke-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Musa Yilmaz-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Naval Daver-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Sylvain Garciaz-24558.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents.ts
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Elias Jabbour-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Ghayas Issa-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Li Yang-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Robert Zeiser-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Sara Zarnegar-Lumley-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Yuchen Liu-24559.pdf
  Oral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Eduardo Magalhaes-24564.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Fanny Gonzales-24564.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Nastassja Scheidegger-24564.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Ramprasad Ramakrishnan-24564.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics V‚ronique Lisi-24564.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Andrew Stiff-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Diego Pereira-Martins-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Francisco Marchi-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Juan Barajas-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Martina Pigazzi-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Yotaro Ochi-24561.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Bettina Nadorp-24562.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Danielle Kirkey-24562.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Isabel Weinhaeuser-24562.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Sergio Rutella-24562.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Chong Chyn Chua-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Corentin Orvain-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Gege Gui-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jacqueline Cook-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jad Othman-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Maddalena Benetton-24563.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Adrian Mosquera Orgueira-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Curtis Lachowiez-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Mark Levis-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Pierre Peterlin-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Romane Joudinaud-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Shai Shimony-24560.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant.ts
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Adriane Halik-24565.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Gregor Hoermann-24565.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Hussein Abbas-24565.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Sander Lambo-24565.pdf
  Oral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response.ts
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Hanna Thorsson-24566.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Ilaria Iacobucci-24566.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Jingliao Zhang-24566.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Lorenz Bastian-24566.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Shunsuke Kimura-24566.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis.ts
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Anna Gurevich Shapiro-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Francesco Corrado-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Guranda Chitadze-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Satoshi Yoshimura-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Sean Tracy-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Willem Cox-24567.pdf
  Oral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment.ts
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alan Cooper-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alicia Beyou-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Andrew Feldman-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics James Phelan-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Natasha Lewis-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Sandrine Roulland-24568.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics.ts
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Alexis Claudel-24569.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Fabrice Jardin-24569.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Julia Paczkowska-24569.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Kyoko Yamaguchi-24569.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Tomohiro Aoki-24569.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc.ts
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Joseph Schroers-Martin-24570.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Pantaleo De Simone-24570.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Reid Merryman-24570.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Wen-Hsuan Wendy Lin-24570.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Xiyue Xu-24570.pdf
  Oral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma.ts
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Dylan Tatterton-24573.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jon Arnason-24573.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jose A. Martinez-Climent-24573.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Ken Young-24573.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Yusuke Isshiki-24573.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma.ts
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Ilja Kalashnikov-24572.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Kanutte Huse-24572.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Matias Autio-24572.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Vignesh Shanmugam-24572.pdf
  Oral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma.ts
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Franck Morschhauser-24574.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Jonathan Friedberg-24574.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Lorenzo Falchi-24574.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Stephen Schuster-24574.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy.ts
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emanuele Zucca-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emmanuel Bachy-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Jillian Gunther-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Loic Ysebaert-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Morgane Cheminant-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Yucai Wang-24577.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL.ts
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Anita Kumar-24576.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Carlo Visco-24576.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Craig Portell-24576.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Eliza Hawkes-24576.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Michael Wang-24576.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents.ts
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Clementine Sarkozy-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Jonathon Cohen-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Juan Alderuccio-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Paolo Strati-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Umberto Vitolo-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Vincent Ribrag-24575.pdf
  Oral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy.ts
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Catherine Diefenbach-24580.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Elizabeth Phillips-24580.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Hun Lee-24580.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Jeremy Abramson-24580.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma.ts
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Eric Jacobsen-24578.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Seok Jin Kim-24578.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Steven Horwitz-24578.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Yuqin Song-24578.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas.ts
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Alison Moskowitz-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Jonathan Brammer-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Pierluigi Porcu-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sanjal Desai-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sarah Rutherford-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Thais Fischer-24579.pdf
  Oral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas.ts
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Adam Olszewski-24582.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Clementine Sarkozy-24582.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jason Westin-24582.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jillian Simard-24582.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Lorenzo Falchi-24582.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas.ts
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Charalambos Andreadis-24583.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Christopher Melani-24583.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Gerhard Held-24583.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Martin Hutchings-24583.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Sabarish Ayyappan-24583.pdf
  Oral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Chan Cheah-24584.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Elizabeth Lihua Budde-24584.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Emil Kyvsgaard-24584.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Peter Riedell-24584.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Trent Wang-24584.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jelena Jelicic-24585.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jinhua Liang-24585.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jordan Goldstein-24585.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Mark Roschewski-24585.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Norbert Schmitz-24585.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Aung Tun-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Gloria Iacoboni-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Jean Koff-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Loretta Nastoupil-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Sanjal Desai-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Viktoriya Zelikson-24588.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Arushi Khurana-24589.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Brian Sworder-24589.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Fabian Frontzek-24589.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Pallawi Torka-24589.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Steven Bair-24589.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Andrew Zelenetz-24586.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Rena Buckstein-24586.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Shinpei Harada-24586.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient.ts
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Bhausaheb Bagal-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL David Hodgson-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Evelyn Orlando-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Kathryn Lurain-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Monica Balzarotti-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Steven Durani-24587.pdf
  Oral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL.ts
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jennifer O Sullivan-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jyoti Nangalia-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Marc Usart-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Matthew Stubbs-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Vignir Helgason-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Yuki Tahira-24591.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery.ts
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Billy Truong-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Charlotte Brierley-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Joseph Kim-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Molly Brakhane-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Nicole Vincelette-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Tim Kong-24590.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models.ts
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Golam Mohi-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Isabelle Becker-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Koki Ueda-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Madeline Caduc-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Naseer Basma-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Warren Fiskus-24592.pdf
  Oral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context.ts
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches David Yeung-24593.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Fadi Haddad-24593.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Jorge Cortes-24593.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Qian Jiang-24593.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Timothy Hughes-24593.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches.ts
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Andreas Hochhaus-24594.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Franck Nicolini-24594.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Frederic Millot-24594.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Susan Branford-24594.pdf
  Oral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication.ts
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Harinder Gill-24595.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Naveen Pemmaraju-24595.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Sanjay Mohan-24595.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Srinivas Tantravahi-24595.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Steffen Koschmieder-24595.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies.ts
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Lindsay Rein-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Nico Gagelmann-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Pankit Vachhani-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Raajit Rampal-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Rithin Nedumannil-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Yu-Hung Wang-24597.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers.ts
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Andrew Kuykendall-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Elliot Stieglitz-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Matthieu Groh-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Prithviraj Bose-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Sudipto Mukherjee-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Tsewang Tashi-24598.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies.ts
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Deepika Dilip-24596.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Ellen Ritchie-24596.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Joachim Goethert-24596.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Justin Watts-24596.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Trine Knudsen-24596.pdf
  Oral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs.ts
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Carmelo Gurnari-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications He Tian (Tony) Chen-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Martina Sarchi-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Noah Salama-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Srinivas Aluri-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Zohar Sachs-24599.pdf
  Oral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications.ts
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Elsa Bernard-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Johann-Christoph Jann-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Julia Montoro-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Luca Lanino-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Rurika Okuda-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Tariq Kewan-24600.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS.ts
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Cristina Astrid Tentori-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Guillermo Garcia-Manero-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Maria Diez-Campelo-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Moshe Mittelman-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Rami Komrokji-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Sandra Huber-24603.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS.ts
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Daniel Nguyen-24601.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Douglas Tremblay-24601.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jacqueline Garcia-24601.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jan Philipp Bewersdorf-24601.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Lok Lam Ngai-24601.pdf
  Oral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS.ts
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Billy Jebaraj-24604.pdf
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Claudio Martines-24604.pdf
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Laura Polcik-24604.pdf
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Prajish Iyer-24604.pdf
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Yi Miao-24604.pdf
  Oral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation.ts
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Armin Riecke-24606.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Jennifer Brown-24606.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Moritz Furstenau-24606.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Othman Al-Sawaf-24606.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Sarka Pavlova-24606.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation.ts
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Andy Rawstron-24605.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Carol Follows-24605.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Jeff Sharman-24605.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Paolo Ghia-24605.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Peter Hillmen-24605.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia.ts
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Constantine Tam-24607.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Brown-24607.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Woyach-24607.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Parag Jasani-24607.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Tanya Siddiqi-24607.pdf
  Oral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Georgina Anderson-24613.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Laura Lucia Cogrossi-24613.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Luz Moreno Rueda-24613.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Yakinthi Chrisochoidou-24613.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Zachary Hunter-24613.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Elizabeth Lightbody-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Faith Davies-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Hsiling Chiu-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Ross Firestone-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Takahiro Kamiya-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Xiaoli Mi-24608.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Deeksha Vishwamitra-24610.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Fumou Sun-24610.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Mansour Poorebrahim-24610.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Maximilian Merz-24610.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Ram Pillarisetti-24610.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Eugenio Morelli-24609.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marcella Kaddoura-24609.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marios Papadimitriou-24609.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Rodger Tiedemann-24609.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Wataru Kuroki-24609.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Anthony Cirrincione-24612.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Camila Guerrero-24612.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Elizabeth Lightbody-24612.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Yubin Kang-24612.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions.ts
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Itziar Cenzano-24611.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Marc-Andrea Baertsch-24611.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Minghao Dang-24611.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Saurabh Zanwar-24611.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Visanu Wanchai-24611.pdf
  Oral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Alireza Tafazzol-24616.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Benjamin Diamond-24616.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Chunrui Li-24616.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Sahar Khan-24616.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Yeasung Lee-24616.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Carmen Gonzalez-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Elizabeth Hill-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Febe Smits-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Nizar Bahlis-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Tadeusz Kubicki-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Yael Cohen-24620.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Carolina Schinke-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Daniel Wong-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Evangelos Terpos-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Martin Kaiser-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Theresia Akhlaghi-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Wenqiang Deng-24618.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Chakra Chaulagain-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Cristina Perez-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Efstathios Kastritis-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Jon Thorir Oskarsson-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Michael Wysota-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Santiago Thibaud-24617.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc..ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Gaurav Agarwal-24615.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Nisha Joseph-24615.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Noemi Puig-24615.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Yered Pita-Juarez-24615.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Darren Pan-24614.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Doris Hansen-24614.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Elise Cellerin-24614.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Michel Delforge-24614.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Sridevi Rajeeve-24614.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma.ts
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Aintzane Zabaleta-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Danai Dima-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Darren Pan-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Junia Vieira dos Santos-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Michel Delforge-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Xiang Zhou-24619.pdf
  Oral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications.ts
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Ajai Chari-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Hang Quach-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Jeffrey Matous-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Paul Richardson-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Sumit Madan-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Wee-Joo Chng-24623.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma.ts
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Cyrille Touzeau-24622.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Maria-Victoria Mateos-24622.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Niels van de Donk-24622.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Ola Landgren-24622.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Omar Nadeem-24622.pdf
  Oral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma.ts
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Efstathios Kastritis-24624.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Jahanzaib Khwaja-24624.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Moshe Gatt-24624.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Thorir Einarsson Long-24624.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Xin Jiang-24624.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis.ts
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Mackenzie Maberry-24625.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Nickolas Tsakmaklis-24625.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Shayna Sarosiek-24625.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Szymon Szymura-24625.pdf
  Oral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders.ts
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Aditiya Rayasam-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Albert Yeh-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Chi Nguyen-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Dongchang Zhao-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Kristina Mott-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Marco Calafiore-24626.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome.ts
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Andri Leo Lemarquis-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution David Granadier-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Fathima Mohamed-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Katja Weinacht-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Kevin Quann-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Lee-Kai Sun-24627.pdf
  Oral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Jufang Chang-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Lydia Lee-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Meixian Huang-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Varsha Sundaresan-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Yusuke Ito-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Zhiliang Bai-24629.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Ivan Cohen-24628.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Jan Mueller-24628.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Mohammad Alhomoud-24628.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Hongwei Ren-24631.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Jingyu Xiang-24631.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Puneeth Guruprasad-24631.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers James Kuzich-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jay Daniels-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jort Van Der Schans-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Kathryn Cappell-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Mathew Angelos-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Zhenlong Li-24633.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Benjamin Goldenson-24630.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Catherine Danis-24630.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Corynn Kasap-24630.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Mylinh Bayle-24630.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Sergio Rutella-24630.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies.ts
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Janaki Manoja Vinnakota-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Ruchi Patel-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Shinpei Harada-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Stefanie Bachl-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Taisuke Kondo-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Yongxian HU-24632.pdf
  Oral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights.ts
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Aibin Liang-24634.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Jens Hillengass-24634.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Matthew Frigault-24634.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Nirav Shah-24634.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas.ts
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Anand Bhagwat-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Claire Roddie-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Elizabeth Lihua Budde-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Fabian Mueller-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Peihua Lu-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Susan Bal-24637.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies.ts
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Jae Park-24636.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Julio Chavez-24636.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Lei Yu-24636.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Pierre Sesques-24636.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Robert Weinkove-24636.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies.ts
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Arjan van de Loosdrecht-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Armin Ghobadi-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Jessica Liegel-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Nirali Shah-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Samer Srour-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Yago Nieto-24635.pdf
  Oral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas.ts
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Adam Kittai-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Alison Sehgal-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Andre Goy-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Jennifer Crombie-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Michael Cook-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Swetha Kambhampati-24638.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data.ts
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Anna Ossami Saidy-24639.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Evandro Bezerra-24639.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Gregory Roloff-24639.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Jay Spiegel-24639.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Surbhi Sidana-24639.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas.ts
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Kai Rejeski-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Karthik Nath-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Mark Hamilton-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Matthew Frigault-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Roni Shouval-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Zimu Gong-24640.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity.ts
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Ash Alizadeh-24641.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Gloria Iacoboni-24641.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Katie Maurer-24641.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Mike Mattie-24641.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Sandeep Raj-24641.pdf
  Oral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors.ts
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Daisuke Araki-24642.pdf
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Kate Markey-24642.pdf
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Laurent Garderet-24642.pdf
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Natalie Holl-24642.pdf
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Yi-Jiun Su-24642.pdf
  Oral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells.ts
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Amado Karduss-24644.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Biqi Zhou-24644.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Filippo Milano-24644.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Reem Alasbali-24644.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Simona Piemontese-24644.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool.ts
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Andrew Artz-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anita Lawitschka-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anthony Sabulski-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Eric Davis-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Madhavi Lakkaraja-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Michael Grimley-24643.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications.ts
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Arpita Gandhi-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hannah Choe-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hao Zheng-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Ibrahim Yakoub-Agha-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Marie Robin-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Xiaoyu Zhang-24646.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies.ts
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Bertram Glass-24645.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Caspian Oliai-24645.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Issa Khouri-24645.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Krzysztof Kalwak-24645.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Rajni Agarwal-24645.pdf
  Oral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia.ts
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Alina Markova-24647.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Jeffery Auletta-24647.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Nikolaos Spyrou-24647.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Yu Akahoshi-24647.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Zachariah Defilipp-24647.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management.ts
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Erik Thiele Orberg-24648.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Haowen Xiao-24648.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Leslie Kean-24648.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Michael Martens-24648.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Xiaoxuan Lai-24648.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology.ts
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Corey Cutler-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Hang Zhang-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Nicoletta Cieri-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Ramzi Abboud-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Robert Zeiser-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Zachariah Defilipp-24649.pdf
  Oral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment.ts
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Alexandria Maurer-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Dustin McCurry-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Hengwei Wu-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Luca Vago-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Nicoletta Cieri-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Shahinaz Gadalla-24651.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes.ts
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Arnon Nagler-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mary Eapen-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mazin Mohamed Abdulsalam-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Rohtesh Mehta-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Sitong Chen-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Zhihui Li-24650.pdf
  Oral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations.ts
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Gordon Cook-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach June-Wha Rhee-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Leyre Bento-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Marc-Andrea Baertsch-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Mazyar Shadman-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Shohei Mizuno-24652.pdf
  Oral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach.ts
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Arnon Nagler-24653.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Johannes Schetelig-24653.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Juan Montoro-24653.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Minoru Kanaya-24653.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Rohtesh Mehta-24653.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection.ts
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Ali Bazarbachi-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Shernan Holtan-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Simona Pagliuca-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Timothy Voorhees-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yuho Najima-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yves Chalandon-24655.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation.ts
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Ali Bazarbachi-24654.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Benjamin Huang-24654.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Iman Abou Dalle-24654.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Zaid Abdel Rahman-24654.pdf
  Oral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification.ts
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Alok Srivastava-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside John DiPersio-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Naoya Uchida-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Simon Chu-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Stefan Radtke-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Vincent Muczynski-24657.pdf
  Oral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside.ts
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Franco Locatelli-24656.pdf
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Haydar Frangoul-24656.pdf
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Julie Kanter-24656.pdf
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Steven Pipe-24656.pdf
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Ulrike Reiss-24656.pdf
  Oral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders.ts
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Anna Montanaro-24658.pdf
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Chao-Yie Yang-24658.pdf
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Lukas Kazianka-24658.pdf
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Monika Toma-24658.pdf
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Samuel Taylor-24658.pdf
  Oral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders.ts
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Arda Durmaz-24659.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Chorom Pak-24659.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Jurik Mutter-24659.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Yoonkyu Lee-24659.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology.ts
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Andrew Srisuwananukorn-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Anna Kamysheva-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Catherine Lecat-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Chen Zhou-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Gianluca Asti-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Yoko Kawamura-24660.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology.ts
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Francisco Marchi-24661.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Gianluca Asti-24661.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Jing Sun-24661.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Vikram Dhillon-24661.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Zhongxun Shi-24661.pdf
  Oral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology.ts
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Ashish Gupta-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Cecily Allen-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Costa Kazadi-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Lucy Fox-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Shiliang Ge-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Steven Hardy-24664.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology.ts
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Charles Jonassaint-24662.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Kim Smith-Whitley-24662.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Layla Van Doren-24662.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Pranav Shrestha-24662.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Robyn Cohen-24662.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education.ts
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Chiara Alessandra Cella-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Ming Y Lim-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Neha Bhasin-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Richard Godby-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Sara Mancuso-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Stacey Fedewa-24663.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders.ts
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Erica Mamauag-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ifeyinwa Osunkwo-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Julie Kanter-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ofelia Alvarez-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Wally Smith-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Yogindra Persaud-24665.pdf
  Oral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum.ts
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Aaron Cohen-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Arti Vaishnav-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Laura Quillen-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Mia Djulbegovic-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Pallavi Ganguli-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Sikander Ailawadhi-24666.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias.ts
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Atharva Karulkar-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Matthew Gromowsky-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Meng-Hsuan Lin-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Patrick Connor Johnson-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Radhika Bansal-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Tonya Cox-24668.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy.ts
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Andrew Hantel-24667.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Chieh Yang-24667.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Jing-Zhou Hou-24667.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Ludovic Fouillet-24667.pdf
  Oral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data.ts
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christa Meyer-24669.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christopher Su-24669.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Marissa Locastro-24669.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Pamela Egan-24669.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Thomas Walsh-24669.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies.ts
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Ashley Hadjis-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Christopher Strouse-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Danielle McQuinn-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Eshana Shah-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Jaime Preussler-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Rahul Mishra-24670.pdf
  Oral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies.ts
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Andrew Kuykendall-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jiasen He-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jordan Schaefer-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Josue Marquez-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Justine Ryu-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Ummul Asfeen-24672.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients.ts
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Charity Oyedeji-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Joseph Walden-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Kim Agrippa-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Oliver Shastri-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Rajagopalan Subramaniam-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Seethal Jacob-24671.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease.ts
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Antonio Risitano-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders George Goshua-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Nora Gibson-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Satoko Ito-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Shoshana Revel-Vilk-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Vincent Ho-24673.pdf
  Oral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma David Cordas dos Santos-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Francesco Marchesi-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Ghulam Rehman Mohyuddin-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Rahul Banerjee-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Roberto Mina-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Shakira Grant-24677.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Adam Kittai-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Amber Koehler-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Andres Noyola-Perez-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Maria Fernandez Turizo-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Rockbum Kim-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Vaishali Dulobdas-24678.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data David Leaf-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Kimberly Saverno-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Mazyar Shadman-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Narendranath Epperla-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Nilanjan Ghosh-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Pere Barba-24675.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Alissa Visram-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Doris Hansen-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Fieke Hoff-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Hira Mian-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Inger Nijhof-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Meera Mohan-24674.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Amy Wang-24676.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Annalynn Williams-24676.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Benoit Tessoulin-24676.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Guillaume Cartron-24676.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Timothy OConnor-24676.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies.ts
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Gin Yi Lee-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Jorge Florindez-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Kaitlin Annunzio-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Mustafa Wasifuddin-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Narendranath Epperla-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Niloufer Khan-24679.pdf
  Oral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma.ts
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Alice Mims-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Amer Zeidan-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Caitlin Elgarten-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Diego Adrianzen Herrera-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Emanuele Angelucci-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Nosakhare Ilerhunmwuwa-24682.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes.ts
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Alma Habib-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Daniel Zheng-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Jeffrey Rubnitz-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michael Grunwald-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michelle Lee-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Teresa Caprice-24681.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities.ts
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Areej El-Jawahri-24680.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Diego Adrianzen Herrera-24680.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Esther Oliva-24680.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Kirollos Hanna-24680.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Valeria Santini-24680.pdf
  Oral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies.ts
  Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Linde Miles-24146.pdf
  Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Mark Dawson-24146.pdf
  Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Seishi Ogawa-24146.pdf
  Scientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies.ts
  Scientific Program Emerging Methodologies to Investigate Platelet Biology Andrew Johnson-24144.pdf
  Scientific Program Emerging Methodologies to Investigate Platelet Biology Anita Eckly-24144.pdf
  Scientific Program Emerging Methodologies to Investigate Platelet Biology Florian Gaertner-24144.pdf
  Scientific Program Emerging Methodologies to Investigate Platelet Biology.ts
  Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Demin Wang-24150.pdf
  Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Rick Kapur-24150.pdf
  Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine Satheesh Chonat-24150.pdf
  Scientific Program Interplay of Coagulation and Complement in Transfusion Medicine.ts
  Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Dachuan Zhang-24143.pdf
  Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Leon Kautz-24143.pdf
  Scientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis.ts
  Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Alexander Marson-24142.pdf
  Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Carl June-24142.pdf
  Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Chiara Bonini-24142.pdf
  Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Dan Kaufman-24142.pdf
  Scientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy.ts
  Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Aswin Sekar-24139.pdf
  Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Laura Pasqualucci-24139.pdf
  Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Mandeep Singh-24139.pdf
  Scientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies.ts
  Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Alan Cantor-24145.pdf
  Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Anna Beaudin-24145.pdf
  Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Shannon McKinney-Freeman-24145.pdf
  Scientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood.ts
  Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Alyssa Kennedy-24137.pdf
  Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Jean Soulier-24137.pdf
  Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Sushree Sahoo-24137.pdf
  Scientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes.ts
  Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Evi Stavrou-24149.pdf
  Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Ioannis Mitroulis-24149.pdf
  Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Kimberly Martinod-24149.pdf
  Scientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis.ts
  Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Jeroen Eikenboom-24141.pdf
  Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Leah Sabin-24141.pdf
  Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Lindsey George-24141.pdf
  Scientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders.ts
  Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Jordan Shavit-24136.pdf
  Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Pavel Davizon-Castillo-24136.pdf
  Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Suzan Williams-24136.pdf
  Scientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome.ts
  Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Daniel Lucas-Alcaraz-24140.pdf
  Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Maria Carolina Florian-24140.pdf
  Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Tiago Luis-24140.pdf
  Scientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis.ts
  Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Elham Azizi-24138.pdf
  Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Fei Chen-24138.pdf
  Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology Rong Fan-24138.pdf
  Scientific Program Spatial Genomic & Epigenomic Profiling in Hematology.ts
  Scientific Program The Evolution of Multiple Myeloma From Inside-Out Eugenio Morelli-24147.pdf
  Scientific Program The Evolution of Multiple Myeloma From Inside-Out Marta Chesi-24147.pdf
  Scientific Program The Evolution of Multiple Myeloma From Inside-Out Tom Cupedo-24147.pdf
  Scientific Program The Evolution of Multiple Myeloma From Inside-Out.ts
  Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Ann Dean-24148.pdf
  Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Gerd Blobel-24148.pdf
  Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Mitchell Weiss-24148.pdf
  Scientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.ts
  Scientific Symposia Alternative Immune Effector Cells Evan Weber-24835.pdf
  Scientific Symposia Alternative Immune Effector Cells James Cronk-24835.pdf
  Scientific Symposia Alternative Immune Effector Cells Marie Bleakley-24835.pdf
  Scientific Symposia Alternative Immune Effector Cells.ts
  Scientific Symposia Multi-Omics Driven Precision Hematology Jun J. Yang-24836.pdf
  Scientific Symposia Multi-Omics Driven Precision Hematology Mika Kontro-24836.pdf
  Scientific Symposia Multi-Omics Driven Precision Hematology Pamela Becker-24836.pdf
  Scientific Symposia Multi-Omics Driven Precision Hematology.ts
  Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Caterina Casari-24833.pdf
  Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Matthew Flick-24833.pdf
  Scientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis.ts
  Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Ami Smith-24834.pdf
  Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Kate Markey-24834.pdf
  Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Marcel van den Brink-24834.pdf
  Scientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies.ts
  Scientific Symposia Understanding Sickle Cell Pathophysiology Enrico Novelli-24837.pdf
  Scientific Symposia Understanding Sickle Cell Pathophysiology Jeffrey Chalmers-24837.pdf
  Scientific Symposia Understanding Sickle Cell Pathophysiology Lucia De Franceschi-24837.pdf
  Scientific Symposia Understanding Sickle Cell Pathophysiology.ts
  Special-Interest Sessions 2023 ASH Guideline Implementation Champions Christina Ruiz-24365.pdf
  Special-Interest Sessions 2023 ASH Guideline Implementation Champions Gabriella Nguyen-24365.pdf
  Special-Interest Sessions 2023 ASH Guideline Implementation Champions.ts
  Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Torsten Haferlach-24388.pdf
  Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Weida Tong-24388.pdf
  Special-Interest Sessions AI in Hematology Where Do You Stand in 2023 Yates Coley-24388.pdf
  Special-Interest Sessions AI in Hematology Where Do You Stand in 2023.ts
  Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Alessandra Ferrajoli-24366.pdf
  Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Ayman Alhejazi-24366.pdf
  Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Vilmarie Rodriguez-24366.pdf
  Special-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions.ts
  Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Aaron Goodman-24159.pdf
  Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Benjamin Tillman-24159.pdf
  Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients David Andorsky-24159.pdf
  Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Shannon Walker-24159.pdf
  Special-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients.ts
  Special-Interest Sessions ASH Grassroots Network Lunch.ts
  Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Julie Wolfson-24153.pdf
  Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Sumit Gupta-24153.pdf
  Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Wendy Stock-24153.pdf
  Special-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults.ts
  Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Deborah Siegal-24152.pdf
  Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Saskia Middeldorp-24152.pdf
  Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Suely Rezende-24152.pdf
  Special-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New.ts
  Special-Interest Sessions Blood and Beyond.ts
  Special-Interest Sessions Junior Faculty Career Development Session Cassandra Josephson-24155.pdf
  Special-Interest Sessions Junior Faculty Career Development Session Oyebimpe Adesina-24155.pdf
  Special-Interest Sessions Junior Faculty Career Development Session Srinivas Devarakonda-24155.pdf
  Special-Interest Sessions Junior Faculty Career Development Session.ts
  Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Alison Loren-24158.pdf
  Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Erica Marsh-24158.pdf
  Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Mindy Christianson-24158.pdf
  Special-Interest Sessions Maternal Health Fertility Preservation in Hematology Care.ts
  Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Alisa Wolberg-24154.pdf
  Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Nicole Gormley-24154.pdf
  Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Saad Usmani-24154.pdf
  Special-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community.ts
  Special-Interest Sessions Special Session on Sickle Cell Disease Centers Alexis Leonard-24422.pdf
  Special-Interest Sessions Special Session on Sickle Cell Disease Centers Julie Kanter-24422.pdf
  Special-Interest Sessions Special Session on Sickle Cell Disease Centers Sophie Lanzkron-24422.pdf
  Special-Interest Sessions Special Session on Sickle Cell Disease Centers.ts
  Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Alexandra Power-Hays-24151.pdf
  Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Allison Burnett-24151.pdf
  Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Geoffrey Barnes-24151.pdf
  Special-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care.ts
  Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Sandhya Panch-24367.pdf
  Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Surbhi Shah-24367.pdf
  Special-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation.ts
  Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ludmila Prokunina-Olsson-24831.pdf
  Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ryan Morin-24831.pdf
  Spotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma.ts
  Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Deborah Siegal-24130.pdf
  Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Sam Schulman-24130.pdf
  Spotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors.ts
  Spotlight Sessions Immunometabolism as a Tool to Advance Cell Therapy.ts
  Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Paolo Ghia-24131.pdf
  Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Zhuoer Xie-24131.pdf
  Spotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL.ts
  Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Srinivas Devarakonda-24830.pdf
  Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Yvonne Efebera-24830.pdf
  Spotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients.ts
  Spotlight Sessions The Mysteries of Factor XI David Gailani-24832.pdf
  Spotlight Sessions The Mysteries of Factor XI Ophira Salomon-24832.pdf
  Spotlight Sessions The Mysteries of Factor XI.ts
  Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution John Mark Sloan-24128.pdf
  Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Lauren Merz-24128.pdf
  Spotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution.ts
  Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Justin Taylor-24132.pdf
  Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Valeria Santini-24132.pdf
  Spotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials.ts
  Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Carlos Ramos-24129.pdf
  Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Jonathan Fisher-24129.pdf
  Spotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes.ts
  Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Amber Yates-24862.pdf
  Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia Timothy Kubal-24862.pdf
  Trainee Didactic Session A Road Less Traveled – Careers Outside of Academia.ts
  Trainee Didactic Session Show Me the Money – Funding Your Research Cassandra Josephson-24865.pdf
  Trainee Didactic Session Show Me the Money – Funding Your Research Ifeyinwa Osunkwo-24865.pdf
  Trainee Didactic Session Show Me the Money – Funding Your Research.ts
  Trainee Didactic Session The International Trainee Journey Andres Gomez-De Leon-24160.pdf
  Trainee Didactic Session The International Trainee Journey Eloisa Riva-24160.pdf
  Trainee Didactic Session The International Trainee Journey.ts
  Trainee Didactic Session What to Ask For in an Interview Alison Walker-24867.pdf
  Trainee Didactic Session What to Ask For in an Interview.ts